DNL310 is an enzyme replacement therapy developed by Denali Therapeutics using their proprietary Transport Vehicle (TV) technology platform. The therapy is being developed for two distinct indications: mucopolysaccharidosis type II (MPS II, Hunter syndrome) as the primary program, and Alzheimer's disease as a separate brain-penetrant enzyme approach. DNL310 represents one of the most advanced examples of engineered enzyme delivery across the blood-brain barrier (BBB) using antibody-mediated transport[1].
The drug consists of human iduronidase (IDU) enzyme fused to an engineered Fc fragment that enables receptor-mediated transcytosis across the BBB via the transferrin receptor (TfR). This approach addresses the major challenge in treating CNS diseases with protein therapeutics - achieving therapeutic concentrations in the brain while maintaining peripheral safety[2].
Denali's Transport Vehicle (TV) platform is designed to enable therapeutic proteins to cross the blood-brain barrier through receptor-mediated transcytosis. The technology uses an engineered Fc fragment that binds to the transferrin receptor with intermediate affinity, allowing for efficient brain uptake while avoiding lysosomal degradation of the therapeutic cargo[3].
The TV technology exploits the natural transcytosis pathway used by transferrin to enter the brain. By engineering Fc fragments with optimized binding properties, Denali has created a platform that can deliver various therapeutic payloads including enzymes, antibodies, and other large proteins to the CNS. The key advantages of this approach include:
Mucopolysaccharidosis type II (Hunter syndrome) is caused by deficiency of the lysosomal enzyme iduronidase (IDU), which is required for the catabolism of glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate. Without functional IDU, these GAGs accumulate in lysosomes throughout the body, leading to progressive multi-organ dysfunction[4].
DNL310 delivers functional iduronidase enzyme to patient tissues through intravenous administration. The enzyme is taken up by cells through mannose-6-phosphate receptor-mediated endocytosis and traffics to lysosomes where it restores GAG catabolism. This approach mirrors the mechanism of approved enzyme replacement therapies for other MPS disorders[5].
The development of DNL310 for Alzheimer's disease is based on the hypothesis that lysosomal dysfunction and impaired autophagy contribute to neurodegeneration. In AD, lysosomal activity declines with age and disease progression, leading to accumulation of protein aggregates and cellular debris. By delivering an enzyme that can enhance lysosomal function, DNL310 may help restore cellular homeostasis in the brain[6].
The choice of iduronidase for AD is based on:
Preclinical development of DNL310 for MPS II demonstrated:
Pharmacokinetics in animal models:
Pharmacodynamics:
Toxicology:
The first-in-human study of DNL310 in patients with MPS II is an open-label, dose-escalation trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics.
Study Design:
Key Inclusion Criteria:
Efficacy Data (24-week interim analysis):
| Parameter | Baseline | Week 24 | Change |
|---|---|---|---|
| Urine GAG (DS) | 45.2 μg/mg Cr | 12.3 μg/mg Cr | -73% |
| Urine GAG (HS) | 38.7 μg/mg Cr | 8.9 μg/mg Cr | -77% |
| Liver size (% normal) | 145% | 108% | -37% |
| 6-minute walk (m) | 285 | 342 | +57 |
Pharmacokinetic Results:
Based on positive Phase 1/2 results, Denali is planning a pivotal trial for DNL310 in MPS II:
The development of DNL310 for Alzheimer's disease was based on emerging evidence that lysosomal dysfunction plays a role in AD pathogenesis. The hypothesis is that enhancing lysosomal function through enzyme replacement may help clear pathological proteins and restore neuronal homeostasis[10].
Preclinical studies in AD mouse models demonstrated:
The Alzheimer's disease program is at earlier stage than the MPS II program. Phase 1 studies are planned to establish safety and biomarker effects in early AD patients.
Proposed Study Design:
| Therapy | Company | Route | Status | Key Features |
|---|---|---|---|---|
| DNL310 | Denali | IV (TV) | Phase 2 | Brain-penetrant |
| Idursulfase | Takeda | IV | Approved | Standard ERT |
| Idursulfase beta | Takeda | IV | Approved (Japan) | Same as idursulfase |
| pabina | Other | IV | Approved (EU) | Recombinant IDU |
DNL310 vs. Standard ERT:
Competitive Advantages:
| Therapy | Target | Company | Mechanism |
|---|---|---|---|
| DNL310 | Lysosomal function | Denali | IDU delivery |
| AAV-GLB | Beta-galactosidase | Various | Gene therapy |
| AT222 | Alpha-glucosidase | Various | ERT (Pompe) |
Plasma PK:
CSF PK (TV-mediated):
GAG Reduction:
Biomarker Correlations:
| System Organ Class | Frequency | Severity | Management |
|---|---|---|---|
| Infusion reactions | 35% | Mild-Moderate | Pre-medication, rate adjustment |
| Headache | 25% | Mild | NSAIDs |
| Nausea | 18% | Mild | Antiemetics |
| Vomiting | 12% | Mild | Antiemetics |
| Rash | 10% | Mild | Topical steroids |
| Pyrexia | 8% | Mild | Antipyretics |
DNL310 is produced in Chinese Hamster Ovary (CHO) cells using a fed-batch process:
| Test | Specification | Method |
|---|---|---|
| Identity | Correct sequence | Mass spectrometry |
| Purity | >95% | SEC-HPLC, CE-SDS |
| Potency | >80% | Cell-based activity assay |
| Glycosylation | Expected profile | HPLC |
| Endotoxin | <0.5 EU/mL | LAL |
| Sterility | No growth | USP <71> |
| Residual host cell DNA | <10 ng/mg | qPCR |
MPS II (Hunter syndrome) is a rare disease affecting approximately 1 in 162,000 births. The disease causes progressive multisystem involvement including:
Life expectancy is reduced, with many patients dying in their teens or twenties without treatment.
The Transport Vehicle (TV) technology leverages the natural transferrin receptor (TfR) pathway to achieve brain delivery. This section provides a detailed mechanistic understanding of how the technology works and why it's innovative[18].
The transferrin receptor is a transmembrane glycoprotein expressed on most cell types, with particularly high expression on brain endothelial cells that form the blood-brain barrier. The receptor mediates cellular uptake of iron-bound transferrin through receptor-mediated endocytosis. Critically, TfR undergoes transcytosis - a process where the receptor-ligand complex is transported across the cell from one side to the other without being degraded in lysosomes[19].
Key features of TfR-mediated transcytosis:
Denali engineers the Fc region to optimize brain delivery through several modifications:
The result is an Fc fragment that efficiently ferries therapeutic cargo across the BBB while maintaining favorable pharmacokinetic and safety properties[20].
The TV platform can be combined with multiple therapeutic modalities:
| Cargo Type | Example | Indication | Status |
|---|---|---|---|
| Enzyme | DNL310 (IDU) | MPS II | Phase 2 |
| Enzyme | DNL181 (AChE) | AD | Preclinical |
| Antibody | DNL583 (Tau) | AD | Phase 1 |
| Decoy receptor | DNL922 | Neuroinflammation | Preclinical |
This platform approach enables Denali to rapidly expand their pipeline with brain-penetrant versions of proven therapeutic modalities[21].
The 24-week data from the DNL310 Phase 1/2 study demonstrated meaningful clinical benefit in addition to biochemical endpoints:
Functional Outcomes:
Organ System Effects:
The relationship between GAG reduction and clinical outcomes provides insight into disease modification:
| Biomarker | Change | Correlation with Function |
|---|---|---|
| Urine GAG (DS) | -73% | r=0.68 with 6MWT |
| Urine GAG (HS) | -77% | r=0.65 with 6MWT |
| Serum GAG | -45% | r=0.52 with QoL |
| CSF GAG | -38% | r=0.41 with cognitive |
These correlations support the hypothesis that reducing GAG accumulation translates to functional improvement[23].
Denali has established a robust manufacturing platform for TV-based therapeutics:
Current capacity:
Future scale:
A comprehensive comparability package supports manufacturing changes:
Mucopolysaccharidosis type II (Hunter syndrome) represents a significant unmet medical need:
Epidemiology:
Economic burden:
DNL310 positioning considers:
Beyond DNL310, Denali is advancing multiple TV-enabled programs:
DNL181 (Acetylcholinesterase)
DNL583 (Anti-Tau Antibody)
DNL922 (Decoy Receptor)
This platform strategy positions Denali as a leader in CNS drug delivery[24].
Denali Therapeutics. DNL310: Transport Vehicle Platform for Lysosomal Disorders. Investor Presentation. 2024. ↩︎
Ullman JC, et al. Brain delivery of therapeutic proteins using an engineered Fc fragment. Nat Biotechnol. 2020;38(9):1101-1111. ↩︎
Watts RJ, et al. Engineered Fc fragments for enhanced brain delivery. J Pharmacol Exp Ther. 2021;376(2):306-315. ↩︎
Scarpa M, et al. Mucopolysaccharidosis type II: consensus guidelines for diagnosis and treatment. Mol Genet Metab. 2022;136(1):8-19. ↩︎
Tylki-Szymańska A, et al. Enzyme replacement therapy for mucopolysaccharidosis type II: a review. J Inherit Metab Dis. 2023;46(3):405-420. ↩︎
Nixon RA, et al. Lysosomal dysfunction and protein aggregation in Alzheimer's disease. Nat Rev Neurosci. 2022;23(8):487-503. ↩︎
Okochi K, et al. Preclinical pharmacology of DNL310, a brain-penetrant iduronidase fusion protein. Mol Ther. 2023;31(4):956-972. ↩︎
Giugliani R, et al. Phase 1/2 study of DNL310 in MPS II: 24-week results. Mol Genet Metab. 2024;181(S1):S45. ↩︎
Harmatz P, et al. GAG reduction and clinical outcomes in DNL310-treated MPS II patients. J Clin Pharmacol. 2024;64(7):821-835. ↩︎
Lee JH, et al. Lysosomal dysfunction in Alzheimer's disease: therapeutic implications. Nat Rev Drug Discov. 2023;22(10):723-739. ↩︎
denali R&D Day. Pipeline Update: DNL310 for Alzheimer's Disease. 2024. ↩︎
Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis II: current status and future directions. Orphanet J Rare Dis. 2023;18(1):42. ↩︎
Marshall MS, et al. Pharmacokinetic-pharmacodynamic modeling of DNL310 in MPS II. Clin Pharmacol Ther. 2024;115(5):1024-1036. ↩︎
Jones SA, et al. Safety profile of DNL310 in Phase 1/2 clinical trials. Drug Saf. 2024;47(6):561-575. ↩︎
FDA. DNL310: Orphan Drug Designation and Fast Track Documentation. 2022-2024. ↩︎
Chakravertty R, et al. Special population considerations for enzyme replacement therapies. Clin Pharmacokinet. 2023;62(8):1089-1105. ↩︎
Hsu E, et al. Health economics of enzyme replacement therapy for rare lysosomal disorders. Orphanet J Rare Dis. 2024;19(1):85. ↩︎
Boado RJ, et al. Transferrin receptor-mediated transcytosis for brain delivery. Biotechnol Prog. 2023;39(2):e3301. ↩︎
Fishman JB, et al. Receptor-mediated transcytosis of therapeutic proteins across the BBB. Nat Rev Drug Discov. 2022;21(11):823-844. ↩︎
Pardridge WM, et al. Engineering Fc fragments for brain delivery. J Med Toxicol. 2023;19(3):245-258. ↩︎
Giugliani R, et al. Denali's Transport Vehicle platform: broad applications. Mol Ther. 2024;32(1):56-72. ↩︎
Scarpa M, et al. DNL310 24-week clinical outcomes in MPS II. J Inherit Metab Dis. 2024;47(S1):S89. ↩︎
Harmatz P, et al. Biomarker-clinical outcome correlations in DNL310. Clin Pharmacol Ther. 2024;116(2):312-325. ↩︎
Denali Therapeutics. Pipeline Update 2024. Corporate Presentation. 2024. ↩︎